💼InvestingWhy Micro-Cap Biotech LENZ Therapeutics Presents a Value Trap Risk for Retail Investors
MarketBrief24 breaks down recent analyst warnings surrounding micro-cap biotech firm LENZ Therapeutics and its flagship presbyopia treatment, VIZZ.
💼InvestingMarketBrief24 breaks down recent analyst warnings surrounding micro-cap biotech firm LENZ Therapeutics and its flagship presbyopia treatment, VIZZ.
Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.